These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

335 related items for PubMed ID: 14520092

  • 1. Development of the Bowman-Birk inhibitor for oral cancer chemoprevention and analysis of Neu immunohistochemical staining intensity with Bowman-Birk inhibitor concentrate treatment.
    Armstrong WB, Wan XS, Kennedy AR, Taylor TH, Meyskens FL.
    Laryngoscope; 2003 Oct; 113(10):1687-702. PubMed ID: 14520092
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Clinical modulation of oral leukoplakia and protease activity by Bowman-Birk inhibitor concentrate in a phase IIa chemoprevention trial.
    Armstrong WB, Kennedy AR, Wan XS, Taylor TH, Nguyen QA, Jensen J, Thompson W, Lagerberg W, Meyskens FL.
    Clin Cancer Res; 2000 Dec; 6(12):4684-91. PubMed ID: 11156220
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Protection against metastasis of radiation-induced thymic lymphosarcoma and weight loss in C57Bl/6NCr1BR mice by an autoclave-resistant factor present in soybeans.
    Evans SM, Van Winkle T, Szuhaj B, Michel KE, Kennedy AR.
    Radiat Res; 1992 Nov; 132(2):259-62. PubMed ID: 1438709
    [Abstract] [Full Text] [Related]

  • 10. Development of difluoromethyl-ornithine and Bowman-Birk inhibitor as chemopreventive agents by assessment of relevant biomarker modulation: some lessons learned.
    Meyskens FL.
    IARC Sci Publ; 2001 Nov; 154():49-55. PubMed ID: 11220668
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Chronicles in drug discovery.
    Moral MA, Khurdayan VK, Bozzo J.
    Drug News Perspect; 2006 Oct; 19(8):485-9. PubMed ID: 17160149
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Detection of Bowman-Birk inhibitor and anti-Bowman-Birk inhibitor antibodies in sera of humans and animals treated with Bowman-Birk inhibitor concentrate.
    Wan XS, Serota DG, Ware JH, Crowell JA, Kennedy AR.
    Nutr Cancer; 2002 Oct; 43(2):167-73. PubMed ID: 12588697
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Preparation and production of a cancer chemopreventive agent, Bowman-Birk inhibitor concentrate.
    Kennedy AR, Szuhaj BF, Newberne PM, Billings PC.
    Nutr Cancer; 1993 Oct; 19(3):281-302. PubMed ID: 8346077
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effects of Bowman-Birk inhibitor concentrate (BBIC) in patients with benign prostatic hyperplasia.
    Malkowicz SB, McKenna WG, Vaughn DJ, Wan XS, Propert KJ, Rockwell K, Marks SH, Wein AJ, Kennedy AR.
    Prostate; 2001 Jun 15; 48(1):16-28. PubMed ID: 11391683
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.